Novel­lusDx col­lab­o­rates with Gene Edit­ing In­sti­tute

BioSpectrum (Asia) - - Company News -

Is­rael-based Novel­lusDx has es­tab­lished a ge­nomic can­cer re­search part­ner­ship with Chris­tiana Care Health Sys­tem’s Gene Edit­ing In­sti­tute to speed-up the devel­op­ment of treat­ments for the dis­ease. Novel­lusDx li­censed gene edit­ing tech­nol­ogy from the in­sti­tute for im­proved the speed and ef­fi­ciency of its di­ag­nos­tic screen­ing tools for can­cer. The tech­nol­ogy is ex­pected to aid in iden­ti­fy­ing ge­netic mech­a­nisms in­volved in the on­set and pro­gres­sion of var­i­ous can­cer types, as well as es­tab­lish high-ef­fi­cacy ther­apy for the dis­ease. As part of the al­liance, Chris­tiana Care will re­ceive roy­al­ties from Novel­lusDx over a tenyear pe­riod. Novel­lusDx re­ceives DNA se­quence in­for­ma­tion from its clin­i­cal part­ners to cre­ate a per­sonal pro­file of the mu­ta­tions from in­di­vid­ual pa­tients. Gene Edit­ing In­sti­tute’s tech­nol­ogy will be used to de­ter­mine the im­pact of each mu­ta­tion on a tu­mour’s sig­nalling path­ways ac­tiv­ity. The gene edit­ing tools will also be used to recre­ate mu­ta­tions in a test sys­tem, fol­lowed by the screen­ing of known can­cer drugs against the mu­ta­tions to val­i­date their ef­fi­ciency. These pro­cesses are be­lieved to help Novel­lusDx in de­ter­min­ing the best drug for in­di­vid­ual pa­tients.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.